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Nasal polyps in adults are characterized by a chronic inﬂammation of the upper airways and by the preferential activation of Th2 cells. In
contrast, IL-17 producing Th17 cells dominate the inﬂammation in nasal polyps of cystic ﬁbrosis (CF) patients.
Method: IL-17A, IL-5, IL-6, IL-8, IL-1β, ECP, MCP-1 and myeloperoxidase expression was determined in tissue homogenates of nasal polyps of
non-CF and CF patients and controls. The cellular source of IL-17A was determined by immuno-histochemistry and FACS analysis. The
functional role of IL-17A in the survival of neutrophils from CF and non-CF patients was tested.
Results: A signiﬁcant upregulation of IL-17A and myeloperoxidase could be observed in nasal polyps from CF-patients. The cellular sources of
IL-17A in nasal polyps were mainly T-lymphocytes. IL-17A was able to modulate the survival of neutrophils in nasal polyps from non-CF
patients; however the survival of neutrophils in CF patients was independent of IL-17A.
Conclusion: The present study shows that IL-17A has an impact on neutrophil survival in adult nasal polyp disease, but not in nasal polyps from
CF patients.
© 2011 European Cystic Fibrosis Society. Published by Elsevier B.V. All rights reserved.Keywords: Nasal polyps; IL-17; Neutrophil1. Introduction
Chronic rhinosinusitis with nasal polyps is clinically charac-
terized by the appearance of nasal polyps in the nasal cavity and
causes typical symptoms such as nasal obstruction, nasal dis-
charge and/or loss of smell. Our group and others described
nasal polyps in white subjects as a T helper 2 polarized disease
which coincides with high IL-5 and IgE concentrations present
in tissue and an influx of mostly eosinophilic granulocytes
[1,2]. However, work from Zhang et al. [3] revealed that
nasal polyps from Chinese patients are clinically similar; how-
ever, they are not dominated by Th2 cells and nearly lack the
expression of IL-5 and eotaxin, but clearly show a Th1/Th17☆ Original Article
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doi:10.1016/j.jcf.2011.11.007polarization with significantly increased levels of IL-17A and
interferon γ. Similarly, patients suffering from cystic fibrosis
(CF), described as a Th17 biased disease, are suffering from se-
vere nasal polyposis. Cystic fibrosis is caused by the mutated
cystic fibrosis transmembrane regulator (CFTR) protein and
can be recognized by the presence of chronic infections and
neutrophil-dominated airway inflammation. Cystic fibrosis is
thus a unique pathological situation in that neutrophils can be
depicted as both an anti-infectious and a proinflammatory cell
[4]. In a previous study published by our group [1,5],
CF-nasal polyps were described as neutrophilic and increased
protein levels of IL-8, IL-1β and MPO were detected in
comparison with normal nasal mucosa. Other groups observed
increased levels of IL-17A and IL-17F in the BAL and sputum
of CF patients compared to control patients [6–8].
The interleukin-17 (IL-17) family consist of interleukins
IL-17A to F, with IL-17A and F being the most abundant
isoforms which are secreted by T cells (Th17 cells) [9], and
NKT cells [10]. IL-17 is known to have various inflammatoryby Elsevier B.V. All rights reserved.
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immunity. One of the first reported functions of IL-17A was
its effect on innate immune cells including neutrophils, mast
cells, and macrophages [11]. Specifically, IL-17A is produced
within 4–8 h after microbial infection and was shown to
enhance neutrophil chemotaxis by promoting IL-6 and IL-8 pro-
duction and to trigger rapid, nonspecific immunity to infectious
agents. The aim of this study was to analyze IL-17A levels in
normal nasal mucosa and nasal polyps and investigate the
functional role of IL-17A on tissue neutrophils. To address
this, we evaluated IL-17A protein levels of normal nasal
mucosa and nasal polyp tissue from CF and non-CF patients
and tested the functionality of IL-17A on the survival of tissue
neutrophils.
2. Material and methods
2.1. Patients
Patients were selected at the department of Otorhinolaryn-
gology of the Ghent University Hospital, Belgium. Inferior
turbinate samples from patients without sinus disease undergo-
ing septoplasty or rhinoseptoplasty were collected as controls
(controls n=16). Samples from patients suffering from adult
nasal polyposis (CRSwNP n=27 and CF-NP n=14) were
obtained during functional endoscopic sinus surgery (FESS)
procedures. CF patients (Table 1) were all clinically stable
before FESS was performed. All patients underwent a skin
prick test to common inhalant allergens. None of the controls
had a history of asthma. The diagnosis of sinus disease was
based on history, clinical examination, nasal endoscopy and
computed tomography (CT) of the paranasal cavities according
to the current European EPOS and American guidelines. The
study was approved by the local Ethical committee of theTable 1
Characteristics of cystic fibrosis patients.
Sample Genetic defect Serum total IgE P. aeruginosa
CF-NP1 ΔF508 ND ND
CF-NP2 Deleted exon 2 24.2 ±
CF-NP3 ΔF508 ND ND
CF-NP4 ΔF508 154 +
CF-NP5 ΔF508+DF5608 b4.4 ±
CF-NP6 ΔF508+Y1092X 4.5 ±
CF-NP7 ΔF508 ND ND
CF-NP8 ΔF508 9.8 –
CF-NP9 ΔF508+1717-1G>A 11.7 ±
CF-NP10 ΔF508 ND ++
CF-NP11 ΔF508 1512 ±
CF-NP12 ** ND ND
CF-NP13 ΔF508 38.1 ±
CF-NP14 ΔF508+E60X 334 +
CF-NP15 ΔF508 ND +++
CF-NP17 Deleted exon 2 55.8 ±
CF-NP18 G970R+G542X 61.3 –
CF-NP19 Q493R+c2909-71G>C 10.2 –
CF-NP20 ΔF508 176.1 ++
**Information not available.
ND: not done.University Hospital Ghent, Belgium. An informed consent
was obtained from each patient and/or its parents, in the case
of CF patients, before collecting material.
2.2. Cytokine measurements in tissue homogenates
The nasal tissue was processed according to methods
already published [2]. Snap-frozen tissues were added to
1 mL of 0.9% NaCl solution (containing protease inhibitors,
Roche Diagnostics) per 0.1 g of tissue. The tissue was then
homogenized with a mechanical homogenizer (B. Braun-
Melsungen, Germany) at 1000 rpm for 5 min on ice. After ho-
mogenization, the suspensions were centrifuged at 3000 rpm
for 10 min at 4 °C, after which the supernatants were separated
and stored at −20 °C until analysis for cytokines and mediators.
Supernatants were assayed for IL-1β, IL-6, IL-8 IL-17A, eosin-
ophilic cationic protein (ECP), myeloperoxidase (MPO) by
using commercially available ELISA kits (Quantikine ELISA,
R&D Systems, UK; MPO was from Oxis International, USA)
and ECP was determined by using the UniCAP system (Phadia,
Uppsala, Sweden).
2.3. Immunohistochemical staining
Paraffin embedded nasal tissue was cut into 5 μm tissue sec-
tions. Sections were deparaffinized and before immunostaining
with anti-IL17A antibody (R&D systems, Abingdon, UK), the
sections were treated with citrate buffer to retrieve the antigen.
For detection a LSAB+kit (DAKO, Heverlee, Belgium) was
used with DAB+as substrate (DAKO).
2.4. Single cell preparation
Fresh human nasal mucosa was transferred to a GentleMACs
Tube (Miltenyi Biotec, Leiden, The Netherlands) with 10 ml of
tissue culture medium (RPMI 1640 (Invitrogen, Ghent,
Belgium)), containing 2 mM LGlutamine (Invitrogen), antibiotics
(50 IU/ml penicillin and 50 μg/ml streptomycin) (Invitrogen) and
2% FBS (Fetal Bovine Serum, Invitrogen) and fragmented with a
scissor into small pieces, followed by a mixing step in the Gentle
MACs (Miltenyi Biotec). The Gentle MACs tube with tissue was
centrifuged for 5 min at 300 g and supernatant was discarded and
replaced by RPMI medium containing 2 mg/ml collagenase
(Worthington, USA) and 0.04 mg/ml DNAse1 (Roche Diagnos-
tics, Belgium). After an incubation of 45 min at 37 °C, a second
mixing step in the GentleMACs was performed. The cell suspen-
sion was dispersed and passed through a 70 μm cell strainer (BD
Bioscience, Erembodegem, Belgium). Red blood cells were
lysed by resolving the pellet in Versalyse (Beckman Coulter,
Suarlée, Belgium) and cells were incubated for 10 min at RT
and after centrifugation the cell pellet was dissolved in RPMI
with 2% FBS.
2.5. Intracellular cytokine analysis
For T helper cytokine analysis, cells were incubated in
RPMI with 10% FBS and treated with 50 ng/ml phorbol 12-
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1 μg/ml ionomycin (Sigma) for 5 h; the last 4 h brefeldin
(eBioscience, Vienna, Austria) was added to block protein
transport. After 5 h cells were collected and fixed for further
immunostaining with antibodies against CD45, CD3, CD4,
CD15 (BD Bioscience Europe, Erembodegem, Belgium) and
IL-17A (eBioscience). Cells were processed using the FACS
CANTO II and analyzed with the FACS DIVA software.
2.6. Neutrophil survival assay
200,000 granulocytes isolated from anti-coagulated blood
(CRSwNP patients n=3 and CF patients n=7; % CD15+cells
between 20 and 60%) were incubated for 24 h with TCM,
10 ng/ml recombinant IL-17A (R&D systems), 10 or 100 ng/
ml of the functional blocking antibody against IL-17A (R&D
systems) and the combination of recombinant IL-17A with
functional blocking antibody against IL-17A. Changes in neu-
trophil apoptosis were checked by using the AnnexinV-FITC
(AV)/7-AAD kit (Beckman Coulter) in combination with the
APC-labeled CD15 antibody (BD Bioscience) on FACS
CANTO II. Neutrophils were identified as early apoptotic
when they were CD15 positive, AV positive and 7-AAD
negative while the living neutrophils were CD15 positive, AV
negative and 7-AAD negative. For the analysis of neutrophil
apoptosis in nasal polyps, 200,000 dispersed nasal polyp cells
(CRSwNP patients n=8 and CF-NP patients n=4) were incu-
bated for 24 h with TCM, 10 or 100 ng/ml of the functional
blocking antibody against IL-17A or 10 ng/ml recombinant
IL-17A (R&D systems) at 37 °C. To be able to work with abso-
lute numbers of cells flow count beads (Beckman Coulter) were
added to the stained tubes. Cells were processed using the
FACS CANTO II and analyzed with the FACS DIVA software.
2.7. Statistics
The data generated in this study were analyzed using the
SPSS software version 18 (IBM, NY, USA). The Mann–
Whitney U-test was applied to evaluate the statistical difference
between the two patient groups. Data comparison within differ-
ent patient groups was performed using the Kruskal–Wallis
test. Correlations were calculated using the Spearman correla-
tion coefficient. P values of 0.05 were regarded as significant.
3. Results
3.1. Cystic fibrosis nasal polyps are T helper 17 skewed
Based on cytokine and mediator measurements, we were
able to differentiate the non-CF group of nasal polyp samples
(n=28) in IL-5 positive (n=19) and IL-5 negative samples
(n=8) (Fig. 1). In contrast to IL-5 positive polyps, CF nasal
polyp samples (n=14) and control samples (n=14) had no de-
tectable IL-5 protein in the tissue homogenate. Analysis of the
protein levels of IL-17A, IL-6 and IL-1β by Luminex revealed
a significant up-regulation of IL-17A in CF-nasal polyps
(Fig. 1) [78.8 pg/ml; 0–519] compared to control [16.5; 16.2–149.4] and IL-5 positive nasal polyp samples [16.4 pg/ml;
16.2–134.5] (pb0.001). We also observed an increase in
IL-17A protein expression in IL-5 negative nasal polyps
[41.15 pg/ml; 16.4–306.5] not different from CF polyp tissue;
however, this increase did not reach significance vs. controls
or IL-5 positive nasal polyp tissue. The pattern of IL-1β
(Fig. 1) and IL-6 (Fig. 1) followed that of IL-17A in cystic
fibrosis, both cytokines were significantly up-regulated in
CF-nasal polyps. MPO concentrations (Fig. 1) in nasal polyps
from cystic fibrosis patients [109951.5 pg/ml; 17455.6–
416021.7] significantly exceeded those in control tissue
[4670.15 pg/ml; 2575.9–12451.7] (pb0.001) and non-CF
patients [3913.05 pg/ml; 443.6–45329]. We found a significant
correlation (Spearman correlation coefficient 0.722, pb0.05)
between IL-17A and MPO in non-CF nasal polyps, however
this correlation could not be found in CF polyps. Confirming
earlier data we observed a strong up-regulation of ECP (Fig. 1e)
in IL-5 positive nasal polyps [9515 μg/l; 2051–26847.3] and
lower ECP levels in IL-5 negative [1130.9 μg/l; 221.4–
14449.7] and CF-nasal polyps [2847.25 μg/l; 458–8232.5].
Analyzing correlations between the mediators in all samples
confirmed this pattern (Table 2). Analyzing the IL-5 negative
nasal polyps a significant correlation between IL-17A and
IL-1β (0.862, p=0.006) was observed.
3.2. Source of IL-17A in nasal polyp tissue
Immunohistochemical staining with the anti-IL-17A anti-
body (R&D systems) on paraffin embedded nasal polyp tissue
from CF and non-CF patients clearly showed the presence of
IL-17A positive cells in both samples (Fig. 2), with a higher
number of positive cells in CF patients, in line with the protein
data (see before). To identify the source of IL-17A in nasal
polyps, we performed FACS analysis of single cell suspensions
of normal nasal mucosa and nasal polyps from CF and non-CF
patients after 5 h PMA/ionomycin stimulation in the presence
of brefeldin. The results for CD45+, CD3+, CD4+, CD15+
and IL-17A positive cells are given in Fig. 3. CD4 T cells
were the major producers of IL-17A, up to 11% of the CD4+
T lymphocytes were able to secrete IL-17A (Fig. 3a).
Analyzing the CD3+CD4+IL-17A+T cell population in
different tissue samples we found a significant increase of
Th17 cells in CF-nasal polyps (pb0.05) compared to control
samples or nasal polyp from non-CF patients (Fig. 3b). Only
a small population (app. 3%) of CD15+ positive granulocytes
was producing detectable levels of IL-17A (Fig. 3c).
3.3. IL-17A modulates the survival of neutrophils in nasal
polyps
Neutrophils in the blood and tissue are under normal condi-
tions short-lived cells, and spontaneously undergo apoptosis.
Therefore we tested for differences in early apoptosis of
neutrophils (CD15+, AV+ and 7-AAD−) between nasal muco-
sa from non-CF or CF patients. Indeed a lower proportion of
tissue neutrophils isolated from CF patients [6.66%; range 1–
17%] showed early apoptosis compared to non-CF tissue
Fig. 1. Measurements of IL-1β, IL-5, IL-6, IL-8, IL-17A, ECP, MPO, MCP-1 and IgE by Luminex and ELISA in 16 controls (C), 19 IL-5 positive nasal polyps
(IL5+), 8 IL-5 negative nasal polyps (IL5−) and 14 nasal polyp from cystic fibrosis (CF) patients. Data are expressed in Box-and-Whisker plots that represent
the median, the upper and lower quartile value. Statistical analysis was performed using Mann–Whitney U-test. The significance level was set at 0.05% (*), at
0.01 (**) and less than 0.001 (***).
196 L. Derycke et al. / Journal of Cystic Fibrosis 11 (2012) 193–200neutrophils [14.57%; range 10–19%], and consequently, a
higher proportion of tissue neutrophils spontaneously survived
(Fig. 4 a–b). Because we observed increased levels of IL-17A
in tissue samples from non-CF and CF patients, we postulated
that IL-17 was involved in the modulation of neutrophil surviv-
al; we approached this hypothesis by adding or blocking IL-17.
First, we tested the ideal concentration of recombinant IL-17A
and functional blocking antibody against IL-17A on granulo-
cytes isolated from healthy buffy coats. 100 ng/ml of anti-IL-Table 2
Correlation between mediators (Spearman's rho) on all studied samples.
CRSwNP IL-1β IL-5 IL-6
IL-1β 1
IL-5 −0.263 ⁎ 1
IL-6 0.652 ⁎⁎ −0.144 1
IL-8 0.305 −0.220 0.407 ⁎
IL-17A 0.504 ⁎⁎ −0.197 0.322 ⁎⁎
MCP1 0.496 ⁎⁎ −0.138 0.487 ⁎⁎
ECP 0.292 ⁎ 0.521 ⁎⁎ 0.210
MPO 0.713 ⁎⁎ −0.534 ⁎⁎ 0.419 ⁎
⁎ Correlation is significant at the 0.05 level.
⁎⁎ Correlation is significant at the 0.01 level.17A could neutralize the anti-apoptotic effect of 10 ng/ml
recombinant IL-17A (data not shown). Consequently, recombi-
nant IL-17 (rIL-17) or a functional blocking antibody against
IL-17 was added to blood neutrophils of non-CF patients
(n=3) or CF patients (n=7). rIL-17 showed a tendency to
decrease the amount of apoptotic neutrophils [untreated 31%;
range 12–63% and rIL-17 12.5%; range 0–40%] isolated
from non-CF patients (Fig. 4c); no significant results were
observed when blood neutrophils from CF patients (Fig. 4d)IL-8 IL-17A MCP1 ECP MPO
1
0.234 1
0.346 ⁎ 0.209 1
0.071 −0.028 0.317 1
0.391 ⁎ 0.528 ⁎ 0.204 0.197 1
Fig. 2. Immunohistochemical detection of IL-17A in nasal polyps from CF and non-CF patients. Pictures are taken at a magnification of 200 and 400 times.
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rIL-17 18.57%; range 0–72%]. Furthermore, the functional
blocking antibody against IL-17 did not change the number of
early apoptotic blood neutrophils in blood samples from non-
CF or CF patients (Fig. 4c–d).
We then tested the role of IL-17 on nasal tissue neutrophils
from non-CF and CF patients. Nasal polyp single cells were
treated with 10 ng/ml recombinant IL-17A, 10 ng/ml or
100 ng/ml anti-IL17A or left untreated for 24 h. IL-17A was
able to decrease the apoptosis of neutrophils in non-CF patients
to 6.3% [range 3–8%] compared to the untreated condition
with 14.5% [range 10–19%] (pb0.05). Moreover, 10 ng/ml
and 100 ng/ml anti-IL-17A had the adverse effect and signifi-
cantly increased the apoptosis of neutrophils to 20.5% [range
13–29%] or 19% [range 13–29%] (pb0.05) (Fig. 4e). In
contrast, equivalent concentrations of rIL-17 or anti-IL17A
could not modulate the apoptosis of tissue neutrophils in cystic
fibrosis patients (Fig. 4f). A higher concentration of 100 ng/ml
anti-IL17A did show a tendency to decrease the survival of
tissue neutrophils in CF patients compared to TCM treated
samples, but failed to reach significance. Thus, IL-17A was
able to modulate the survival of nasal polyp neutrophils in
non-CF, but not in CF-patients.
4. Discussion
In the present study the expression of IL-17A in nasal polyps
of CF and non-CF patients was investigated and its role on thesurvival of neutrophils was tested. CF also referred to as Th17
disease, can be recognized by a strong infiltration of neutrophils
in the diseased tissue. We could observe significantly more
IL-17A protein in CF nasal polyps and a tendency for the
IL-5 negative subgroup of polyps compared to control tissue.
In the upper airways, the possible cellular sources for IL-17A
are reported to be T lymphocytes, neutrophils, eosinophils,
plasma cells, mast cells and serous glands [12]. As we demon-
strate here, the cellular sources of IL-17A, as determined by
immunohistochemistry and FACS analysis, were primarily
CD4 T helper cells and a minor fraction of granulocytes. Our
results confirmed the observations by Saitoh et al. [13] that
IL-17A predominantly coincides with CD4+ lymphocytes and
granulocytes. Th17 cells may play an important role in chronic
airway inflammatory diseases like asthma and other allergic
diseases. The increased expression of IL-17A in the lung was
proposed to induce an increased migration of airway neutro-
phils via up-regulation of chemo-attractants like IL-8 and
other neutrophil-activating cytokines. Similar mechanisms
may apply to the upper airways [14,15]. However, there exists
some controversy about the importance of IL-17A for the main-
tenance of tissue neutrophils [16,17]; we therefore tested the
effect of IL-17A on neutrophil survival. We here report for
the first time that IL-17A can stimulate the survival of neutro-
phils in the nasal mucosa of non-CF patients, but has little
impact on neutrophils of CF polyps. Neutrophils are the key
components of the first line defense against bacterial and fungal
pathogens; they are usually short-lived cells, which die
Fig. 3. The cellular source of IL-17A was determined by FACS analysis of PMA/ionomycin stimulated nasal polyp cells in the presence of brefeldin. Cells were
stained with CD45, CD3, CD4, CD15 and IL-17 or isotype control (mIgG1) antibodies. (A) Up to 11% of the CD4-positive cells were IL-17 positive cells.
(B) Comparison of the number of IL-17A-CD4+ T lymphocytes (corrected for the amount of CD3+ cells in the tissue) between control and non-CF and non-CF
patients. (C) Detection of IL-17 A positive granulocytes (CD15+).
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recognized by macrophages and this is essential to resolve in-
flammation. The prolongation of the life span of neutrophils,
in contrast, may be essential for the long-term effectiveness
against pathogens. In CF, next to an increased migration of neu-
trophils [18], a delayed neutrophil apoptosis is also observed
and this might explain the persistence of neutrophils at the
inflammation sites. We here observed an increase in survival
of tissue neutrophils from CF patients compared to non-CF pa-
tients, confirming earlier publications [19,20] that neutrophils
from CF patients undergo delayed apoptosis, thereby slowing
down their removal by macrophages and potentiating airway
inflammation. Different authors suggested that neutrophils
from CF patients have disturbed functions: disturbed Na+/H+
transport, an increase in MPO secretion and a disturbed regula-
tion of intercellular pH; this could be attributed to a defect in
CFTR function in the tissue neutrophils [21–24]. Not only the
CF genotype but also the local environment may modify the
functional properties of the neutrophils [25]. Indeed, also in
the nasal polyp homogenates, very high concentrations ofMPO were measured. Disturbed neutrophil functions were ob-
served not only in CF homozygotes but also in the heterozygote
parents of CF patients providing a strong evidence for genetic
defects in the tissue neutrophils. Moreover, Petit-Bertron et al.
[26] observed that airway neutrophils from CF-patients had
enhanced levels of TLR4 and these neutrophils spontaneously
released high levels of IL-8 that were not further enhanced by
microbial activators nor inhibited by recombinant IL-10. In
contrast, the airway epithelial cells from CF patients have less
TLR4 expression compared to normal bronchial epithelial
cells [27], responsible for decreased innate immune responses
and contributing to the chronic character of the infection.
In this study we demonstrate that IL-17A was able to
prolong the survival of tissue neutrophils from non-CF nasal
polyp patients, however, this was not the case in nasal polyps
from CF patients. Moreover, neutrophils isolated from the
blood of non-CF and CF-patients gave comparable results:
IL-17A could decrease the apoptosis in non-CF patients but
not in CF patients. Recently Pelletier et al. [28] discussed
that neutrophils lack the IL-17R receptor and consequently
Fig. 4. IL-17A modulating the survival of tissue neutrophils. Nasal polyps from non-CF and CF patients were dispersed and the apoptosis of CD15+ cells was
analyzed after 24 h by staining with specific apoptosis markers: annexin V and 7-AAD. Analysis was performed of the spontaneous early apoptosis (CD15+,
AV+, 7-AAD−) (A) and the living neutrophils (CD15+, AV−, 7-AAD−) (B) after 24 h in culture medium of non-CF and CF patients. Isolated neutrophils from
anti-coagulated blood from non-CF (C) or CF patients (D) were treated with 10 μg/ml recombinant IL-17A, 10 μg/ml or 100 μg/ml anti-IL-17A or TCM for 24 h;
the percentage of early apoptosis is calculated. Single cell suspension prepared from nasal polyp of non-CF (E) and CF patients (F) were treated with 10 μg/ml
recombinant IL-17A, 10 μg/ml or 100 μg/ml anti-IL-17A or TCM for 24 h. Data are expressed in Box-and-Whisker plots that represent median, the upper and
lower quartile value. Statistical analysis was performed using Kruskal-Wallis test. The significance level was set at 0.05% (*) or at 0.01 (**).
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proved the presence of IL-17R on neutrophils [29] and Th17
cells could also activate neutrophils through the release of
GM-SCF, interferon-γ or TNF-α [16,30]. In the tissue single
cell suspension from non-CF patients we found a clear effect
on the survival of neutrophils after adding IL-17A, a Th17
cell product. However, we cannot claim that the effects we
observed were the consequence of a direct binding of IL-17A
to the IL-17 receptor on tissue neutrophils; IL-17A could also
activate other cells than neutrophils and indirectly lead to in-
creased survival of nasal polyp neutrophils. In line with this,
analyzing the supernatants of IL-17 stimulated nasal polyp
cells we were able to detect an increase of GM-SCF and
MCP-1 in the supernatant of the IL-17A stimulated cultures(data not shown). The same indirect activity of IL-17 may be
true for the stimulation of blood neutrophils.
The present study provides evidence that IL-17A protein
expression is upregulated in nasal polyps from non-CF and
CF patients. IL-17 is capable of improving the survival of
neutrophils in blood and especially nasal mucosa of non-CF
patients either directly or indirectly but does not seem to be
involved in the survival of neutrophils in CF patients.
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